1. Home
  2. PTHL vs NSPR Comparison

PTHL vs NSPR Comparison

Compare PTHL & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTHL
  • NSPR
  • Stock Information
  • Founded
  • PTHL 1998
  • NSPR 2005
  • Country
  • PTHL China
  • NSPR United States
  • Employees
  • PTHL N/A
  • NSPR N/A
  • Industry
  • PTHL
  • NSPR Medical/Dental Instruments
  • Sector
  • PTHL
  • NSPR Health Care
  • Exchange
  • PTHL Nasdaq
  • NSPR Nasdaq
  • Market Cap
  • PTHL 85.4M
  • NSPR 75.1M
  • IPO Year
  • PTHL 2024
  • NSPR N/A
  • Fundamental
  • Price
  • PTHL $18.50
  • NSPR $2.24
  • Analyst Decision
  • PTHL
  • NSPR Strong Buy
  • Analyst Count
  • PTHL 0
  • NSPR 2
  • Target Price
  • PTHL N/A
  • NSPR $4.50
  • AVG Volume (30 Days)
  • PTHL 1.0M
  • NSPR 362.0K
  • Earning Date
  • PTHL 02-11-2025
  • NSPR 08-05-2025
  • Dividend Yield
  • PTHL N/A
  • NSPR N/A
  • EPS Growth
  • PTHL N/A
  • NSPR N/A
  • EPS
  • PTHL N/A
  • NSPR N/A
  • Revenue
  • PTHL $448,196.00
  • NSPR $7,027,000.00
  • Revenue This Year
  • PTHL N/A
  • NSPR $4.85
  • Revenue Next Year
  • PTHL N/A
  • NSPR $113.47
  • P/E Ratio
  • PTHL N/A
  • NSPR N/A
  • Revenue Growth
  • PTHL N/A
  • NSPR 8.49
  • 52 Week Low
  • PTHL $1.32
  • NSPR $1.99
  • 52 Week High
  • PTHL $22.34
  • NSPR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • PTHL N/A
  • NSPR 41.35
  • Support Level
  • PTHL N/A
  • NSPR $1.99
  • Resistance Level
  • PTHL N/A
  • NSPR $2.33
  • Average True Range (ATR)
  • PTHL 0.00
  • NSPR 0.15
  • MACD
  • PTHL 0.00
  • NSPR -0.02
  • Stochastic Oscillator
  • PTHL 0.00
  • NSPR 47.50

About PTHL Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: